Recent Quotes (30 days)

You have no recent quotes
chg | %

Cardiome Pharma Corp.  

(Public, TSE:COM)   Watch this stock  
Find more results for COM
-0.01 (-0.12%)
Oct 21 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 8.44 - 8.64
52 week 3.77 - 12.02
Open 8.56
Vol / Avg. 2,325.00/16,590.00
Mkt cap 142.17M
P/E     -
Div/yield     -
EPS -1.44
Shares 16.52M
Beta 1.07
Inst. own     -
Aug 13, 2014
Cardiome Pharma Corp at Canaccord Genuity Growth Conference
Aug 11, 2014
Q2 2014 CARDIOME PHARMA CORP Earnings Release
Aug 11, 2014
Q2 2014 Cardiome Pharma Corp Earnings Call

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -55.30% 105.81%
Operating margin -52.26% 91.71%
EBITD margin - -295.88%
Return on average assets -34.66% 10.36%
Return on average equity -56.32% 31.30%
Employees 75 -
CDP Score - -


+1-604-6776905 (Phone)
+1-604-6776915 (Fax)

Website links


Cardiome Pharma Corp. (Cardiome) is a research-based biopharmaceutical company. The Company is focused on the discovery, development and commercialization of new therapies. It has one product, BRINAVESS, approved for marketing in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. The Company�s clinical programs are also focused on the treatment of atrial fibrillation, an arrhythmia (or abnormal rhythm) of the upper chambers of the heart. Cardiome also has several pre-clinical projects directed at various therapeutic indications. The Company operates primarily in one business segment with all of its assets located in Canada and operations located in Canada, the United States, Switzerland and the United Kingdom. In March 2012, the Company announced that Merck & Co., Inc. (Merck) discontinued further development of vernakalant (oral). In November 2013, Cardiome Pharma Corp. completed the acquisition of Correvio LLC.

Officers and directors

Robert W. Rieder Chairman of the Board
William L. Hunter M.D. President, Chief Executive Officer, Director
Age: 50
Jennifer Archibald Chief Financial Officer
Sheila M. Grant Chief Operating Officer
Karim Lalji Chief Commercial Officer
Richard M. Glickman Lead Independent Director
W. James O'Shea Director
Peter W. Roberts CPA Independent Director
Harold H. Shlevin M.D., Ph.D., Independent Director
Age: 63